A rare inherited neuromuscular disorder (genetically confirmed)
TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.
Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.
All answers match the protocol.
Population and eligibility
Design
Patient burden
Operations
Environment
Build a site
A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.
Poland recruits fastest per site, at 0.092 a month
Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted
Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.
Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).
Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).
Show data
| Factor | United States | United Kingdom | Spain | Poland | Turkey | India |
|---|---|---|---|---|---|---|
| Therapeutic area | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 |
| Country | 0.075 | 0.085 | 0.100 | 0.140 | 0.100 | 0.110 |
| Site type | 0.074 | 0.084 | 0.099 | 0.143 | 0.098 | 0.106 |
| Track record | 0.073 | 0.082 | 0.097 | 0.140 | 0.096 | 0.104 |
| Protocol and population | 0.073 | 0.082 | 0.097 | 0.140 | 0.096 | 0.104 |
| Patient acceptability | 0.044 | 0.049 | 0.058 | 0.084 | 0.058 | 0.063 |
| Competing trials | 0.048 | 0.054 | 0.064 | 0.092 | 0.063 | 0.069 |
What this design does to the sites needed
To finish by March 2027 with 85% confidence, this design needs about 67 sites, the same as the protocol as written.
| Country | Per site per month, protocol as written | With this design | Change | Sites needed, protocol | With this design |
|---|---|---|---|---|---|
| United States | 0.048 | 0.048 | – | 0 | 0 |
| United Kingdom | 0.054 | 0.054 | – | 0 | 0 |
| Spain | 0.064 | 0.064 | – | 0 | 0 |
| Poland | 0.092 | 0.092 | – | 41 | 41 |
| Turkey | 0.063 | 0.063 | – | 11 | 11 |
| India | 0.069 | 0.069 | – | 15 | 15 |
Risks these answers switch on
Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.
Protocol and design
PD-12Biomarker-selected population with low marker prevalence Grade B
- Effect
- Negative; 37.6% actionable and 17.8% assigned in NCI-MATCH; 39 to 70% amyloid-negative at screening; MASH screen failure 56%.
- What helped
- Central screening at scale (1,117 sites); EHR and registry pre-screening.
- What did not
- not found
- Sources
- Flaherty 2020; Sevigny 2016; Sperling 2020; Souza 2025
PM-05Screen failure is high and varies widely by therapeutic area Grade A
- Effect
- Cuts randomised patients per screened: 36.3% overall and rising, CNS 57%, rare disease 81% ineligible, inflammatory bowel disease 43% to 53%, heart failure outcome trials 42% to 48%, COPD 37% to 42%, oncology 34% to 51%.
- What helped
- not found
- What did not
- Protocol planning assumptions of 10% for asthma and 20% for COPD were exceeded two to four times over in three COPD Phase III programmes.
- Sources
- Tufts CSDD 2019; Tufts CSDD 2012; IBD trials analysis 2025; UCSD 2022; Tata 2023; DAPA-HF and EMPEROR-Reduced dispositions2; COPD letter
PB-10Older adults under-enrolled Grade A
- Effect
- People aged 65 and over were 25% of trial entrants against 63% of cancer patients; trial median age 6.49 years below the population; 70 and over are 24% of FDA-registered trial participants against 42% of the cancer population.
- What helped
- Coverage policy raised 65 and over accrual (Unger 2006); broader eligibility and fewer performance-status cut-offs narrow the gap (Ludmir 2019).
- What did not
- Physician geriatric education, cluster RCT across 126 institutions, no effect (Kimmick 2005).
- Sources
- Hutchins 1999; Ludmir 2019; Sedrak 2021; FDA Snapshots 2024
PD-05Placebo or no-added-treatment control arm Grade B
- Effect
- Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
- What helped
- All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
- What did not
- not found
- Sources
- Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
- Effect
- Negative association only; poor accrual 23% against 16%.
- What helped
- not found
- What did not
- not found
- Sources
- Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
- Effect
- Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
- What helped
- Open or PROBE design where scientifically acceptable.
- What did not
- User-tested information leaflets added 1 point, no effect.
- Sources
- Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
- Effect
- Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
- What helped
- Open-label or pragmatic design where scientifically acceptable (high certainty).
- What did not
- not found
- Sources
- Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-07Unequal randomisation ratio used to aid recruitment Grade C
- Effect
- Unclear; 57% of trials give no rationale and no recruitment benefit is documented.
- What helped
- not found
- What did not
- The claimed recruitment benefit is unproven.
- Sources
- Dumville 2006
PD-03Procedural and visit burden (visits, blood draws, questionnaires) Grade B
- Effect
- Negative; burden score predicts screen failure, trial duration, and amendments (p < 0.01); oncology plans 29 visits against 16.
- What helped
- Score burden at design; prune non-core procedures, which are 22 to 25% of all procedures.
- What did not
- Sites rate decentralised trials as more burdensome for patient-facing procedures.
- Sources
- Smith 2021; Dirks 2025; Getz 2023
S-24Protocol complexity and site burden Grade B
- Effect
- Negative: procedures up 40.6%, sites per protocol up 60.1%, and enrolment duration up 36.9% (2010 to 2020); 70% of site staff say trials are much harder; about one-third of data collected is non-core.
- What helped
- Remove non-core data and procedures. Take site input on design.
- What did not
- not found
- Sources
- Clinical Trial Vanguard 2024; WCG 2024; Tufts CSDD 2022; PharmaVoice 2025
EB-17Follow-up burden and duration Grade C
- Effect
- Negative; trials with final follow-up beyond 18 months recruit at 0.71 per centre per month against 1.29 for follow-up within a month (p=0.054); time commitment is a key deterrent in the qualitative synthesis.
- What helped
- Reducing visit burden (CTTI, not quantified).
- What did not
- not found
- Sources
- Jacques 2022; Houghton 2020
PD-20Decentralised elements Grade C
- Effect
- Unclear; modelled value only; sites split on whether they add or remove burden.
- What helped
- Hybrid elements for follow-up visits.
- What did not
- A fully remote trial under-recruited despite a very large outreach funnel.
- Sources
- FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
Site
S-06Site type: activation speed Grade A
- Effect
- Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
- What helped
- Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
- What did not
- Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
- Sources
- Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
PM-02Academic and hospital sites, and sites new to the sponsor, take longer to activate Grade B
- Effect
- Delays activation by months: 8.1 to 9.4 months for academic medical centres against 4.4 to 4.8 for independent sites, 12.9 against 7.9 months from pre-study visit to first patient, and 35.6 weeks for new sites against 25.7 for repeat sites.
- What helped
- not found
- What did not
- not found
- Sources
- WCG Data Intelligence 2023 to 2025; Tufts CSDD 2012; Tufts CSDD 2018
S-04Past performance as a predictor Grade B
- Effect
- Positive but modest: Spearman 0.13 to 0.16 for historical rate alone and 0.37 to 0.46 with patient-volume data; well-performing sites have a 70% higher chance of out-performing; trial-manager predictions reach 82% sensitivity but 32% specificity.
- What helped
- Combine historical rate with real-world patient volume, referral flow, and research experience. Guided prediction forms with red flags.
- What did not
- Historical performance alone. Unguided judgement after the initiation visit.
- Sources
- Getz 2011; Hulstaert 2024; Bruhn 2019; Yang 2018; Ninh 2026